MedPath
HSA Approval

ELLA TABLET 30MG

SIN13979P

ELLA TABLET 30MG

ELLA TABLET 30MG

June 21, 2011

HYPHENS PHARMA PTE. LTD.

HYPHENS PHARMA PTE. LTD.

Regulatory Information

HYPHENS PHARMA PTE. LTD.

HYPHENS PHARMA PTE. LTD.

Therapeutic

Prescription Only

Formulation Information

TABLET

**4.2 Posology and method of administration** Posology The treatment consists of one tablet to be taken orally as soon as possible, but no later than 120 hours (5 days) after unprotected intercourse or contraceptive failure. The tablet can be taken with or without food. If vomiting occurs within 3 hours of Ella intake, another tablet should be taken. Ella can be taken at any moment during the menstrual cycle. Pregnancy should be excluded before Ella is administered. _Special populations_ _Renal or hepatic impairment:_ In the absence of specific studies, no specific dose recommendations for Ella can be made. _Severe hepatic impairment:_ In the absence of specific studies, Ella is not recommended. _Children and adolescents:_ A limited number of women under 18 years were included in clinical trials of Ella. Method of administration Oral use.

ORAL

Medical Information

**4.1 Therapeutic indications** Emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure.

**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Pregnancy.

G03AD02

ulipristal

Manufacturer Information

HYPHENS PHARMA PTE. LTD.

CENEXI

Active Ingredients

Ulipristal acetate

30.00 mg

Ulipristal

Documents

Package Inserts

Ella Tablet 300mg PI.pdf

Approved: July 27, 2022

Download

Patient Information Leaflets

Ella Tablet 300mg PIL.pdf

Approved: July 27, 2022

Download
© Copyright 2025. All Rights Reserved by MedPath